Nivolumab improves lung cancer survival in 80%
Discover how nivolumab improves lung cancer survival rates, with 80% of patients alive after five years in a groundbreaking study on immunotherapy.
Category
Discover how nivolumab improves lung cancer survival rates, with 80% of patients alive after five years in a groundbreaking study on immunotherapy.